KEI and Public Citizen Joint Comments on NIH License to Leyden for Coronavirus Treatment

On November 3, 2023, Knowledge Ecology International (KEI) and Public Citizen (PC) submitted joint comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: Human Monoclonal Antibodies That Broadly Target Coronaviruses” (88 FR… Continue Reading

INB 7: Written statement by Knowledge Ecology International

INB 7 Written statement by Knowledge Ecology International November 2023 The current draft of the pandemic accord includes provisions on limitations and exceptions to intellectual property rights that while well intentioned, are problematic. Parties do not need to refer to… Continue Reading

INB 7: Oral statement by Knowledge Ecology International

On Monday afternoon, 6 November 2023, Knowledge Ecology International (KEI) delivered the following oral statement (in person) at the 7th meeting of the World Health Organization’s (WHO) Intergovernmental Negotiating Body (INB). INB 7 Oral statement by Knowledge Ecology International 6… Continue Reading

Save the date – 30 October 2023 – KEI roundtable on the advanced, unedited INB pandemic treaty text (October 2023 version)

Focused discussions on article 9 (Research and development) and article 11 (Transfer of technology and know-how) Monday,30 October 2023 15h30 UTC to 17h30 UTC 16h30 CET to 18h30 CET 11h30 EDT to 13h30 EDT On Monday, 30 October 2023, KEI… Continue Reading

KEI Comments Regarding NIH Proposed License T Cell Cancer Therapy to Moonlight Bio

On October 12, 2023, Knowledge Ecology International (KEI) filed comments regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered T Cell Therapies for the Treatment of Cancer” by the National Institutes of Health (NIH) to… Continue Reading

Scarlet TCR: Comments on a NIH prospective exclusive patent license for treatment of HPV cancers

Updates: Senator Sanders Sends Letter to HHS Inspector General Urging Investigation of Exclusive Patent License for NIH-funded Cancer Therapy, Press Release. October 23, 2023. David Dayen, “Sanders Seeks Investigation of NIH Licensing Practices: The senator wants the inspector general to… Continue Reading

KEI Comments to CMS Regarding Imbruvica (INN:Ibrutinib) R&D (regarding Medicare pricing negotiations)

On October 2, 2023, Knowledge Ecology International submitted written comments to the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Medicare Price Negotiation public consultation process. CMS is hosting a series of patient-focused listening sessions this fall,… Continue Reading

KEI Comments on NIH License to EnZeta Immunotherapies for Solid Tumors

On August 28, 2023, Knowledge Ecology International (KEI) provided comments to the National Institutes of Health (NIH) objecting to the “Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors” (88 FR… Continue Reading